Organ Preservation in Patients With a Good Clinical Response After (Chemo)Radiation for Rectal Cancer: Defining the Role of Additional Contact X-ray Brachytherapy Versus Extending the Waiting Interval and Local Excision

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Radiation, Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this prospective phase II feasibility study is to evaluate two additional local treatment options in rectal cancer patients with a good clinical response after neoadjuvant (chemo)radiation: contact x-ray brachytherapy versus extension of the waiting interval with or without local excision, and to investigate which rate of organ preservation can be achieved.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• histologically verified adenocarcinoma above the dentate line and within 10cm of the anal verge;

• neoadjuvant short-course radiotherapy for patients with 1) IRC and delayed response evaluation according to the Dutch national guidelines (cT1-3, cN1-2 lymph nodal status, no involved MRF or cT3c-d, N0-1 lymph nodal status without pres-ence of significant distant metastases) without full dose chemotherapy in the inter-val (e.g. Rapido-scheme) or 2) LARC due to comorbidity or frailty; OR

• neoadjuvant long-course radiotherapy (chemoradiation) for patients with 1) LARC according to the Dutch national guidelines (cT4 tumour, cN2 lymph nodal status, lateral lymph node involvement, and/or involved MRF, without the presence of significant distant metastases) or 2) early rectal cancer or IRC and a strong wish for organ preservation;

• clinically near-complete response or a small residual tumour mass \<3 cm;

• technically feasible to perform both treatment options (contact x-ray brachytherapy or local excision);

• age \>18 years;

• written informed consent.

Locations
Other Locations
Netherlands
Antoni van Leeuwenhoek
RECRUITING
Amsterdam
Ijsselland Hospital
RECRUITING
Capelle Aan Den Ijssel
Deventer Hospital
RECRUITING
Deventer
Catharina Hospital
RECRUITING
Eindhoven
Medical Center Leeuwarden
RECRUITING
Leeuwarden
Radbouw University Medical Centre
RECRUITING
Nijmegen
Isala
RECRUITING
Zwolle
Contact Information
Primary
Barbara M Geubels, MD
b.geubels@nki.nl
0205129001
Backup
Brechtje A Grotenhuis, MD, PhD
b.grotenhuis@nki.nl
020 239 9111
Time Frame
Start Date: 2021-04-16
Estimated Completion Date: 2029-03
Participants
Target number of participants: 168
Treatments
Experimental: Contact x-ray brachytherapy
Contact x-ray brachytherapy will be given applied after randomisation with a maximum interval of 14 weeks after finishing the neoadjuvant (chemo)radiation. Contact x-ray brachytherapy consists of three fractions of 30Gy per fraction applied to the tumour, with a 2 week interval between each boost. Response evaluation takes place every 3 months thereafter. Patients in whom a clinical complete response is detected during follow-up are offered a watch-and-wait approach; patients in whom an incomplete response or disease progression is noted, completion or salvage TME-surgery is advised.
Experimental: Extending the waiting interval, with or without local excision
The waiting interval will be extended with 6-8 more weeks after the first response evaluation, followed by a second (or third in case of ongoing response) re-assessment. Patients with a clinical complete response at the time of the second (or third) response evaluation will be offered a watch-and-wait approach without any surgical treatment. Patients with a remaining small lesion will be offered transanal local excision. Depending on the final pathological staging after local excision, patients are categorized as low-risk or high-risk, and will be offered a watch-and-wait strategy or completion TME-surgery, respectively.
Related Therapeutic Areas
Sponsors
Collaborators: Catharina Ziekenhuis Eindhoven, ZonMw: The Netherlands Organisation for Health Research and Development
Leads: The Netherlands Cancer Institute

This content was sourced from clinicaltrials.gov